Goldman Sachs’s Apellis Pharmaceuticals APLS Stock Holding History

Goldman Sachs’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,000	Closed	-$364K	–	6322
2025 Q2	$364K	Buy	+21,000	New	+$389K	﹤0.01%	5345
2023 Q3	–	Sell	-23,400	Closed	-$2.13M	–	5525
2023 Q2	$2.13M	Buy	+23,400	New	+$2.02M	﹤0.01%	3835
2023 Q1	–	Sell	-15,000	Closed	-$776K	–	5895
2022 Q4	$776K	Buy	+15,000	New	+$796K	﹤0.01%	4589
2020 Q2	–	Sell	-20,000	Closed	-$536K	–	5180
2020 Q1	$536K	Buy	20,000 +7,700	+63%	+$273K	﹤0.01%	4174
2019 Q4	$377K	Buy	+12,300	New	+$340K	﹤0.01%	4649

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs's APLS Position: Q1 2026 in Review

Goldman Sachs increased its Apellis Pharmaceuticals (APLS) stake by 947% in Q1 2026, buying an estimated $38.6M and bringing the position to 1,980,144 shares worth $79.7M. The position accounts for 0.01% of the portfolio, ranked #1201.

Goldman Sachs first reported a position in APLS in Q2 2018 and has held it in 32 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Goldman Sachs held 1,980,144 shares of Apellis Pharmaceuticals worth $79.7M as of Q1 2026.
Goldman Sachs bought 1,790,939 Apellis Pharmaceuticals shares in Q1 2026, an estimated $38.6M.
Apellis Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1201 holding.
Goldman Sachs first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.